Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.2000 (-2.16%) ($5.2000 - $5.2000) on Fri. Dec. 31, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.95% (three month average) | RSI | 22 | Latest Price | $5.2000(-2.16%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.9% a day on average for past five trading days. | Weekly Trend | AUTL declines -5.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(66%) IBB(60%) IBUY(58%) ARKG(55%) ARKK(54%) | Factors Impacting AUTL price | AUTL will decline at least -2.475% in a week (0% probabilities). VIXM(-39%) VXX(-31%) TLT(-23%) SHY(-21%) TIP(-19%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.475% (StdDev 4.95%) | Hourly BBV | -0.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-12.26(-335.77%) | Resistance Level | $5.69 | 5 Day Moving Average | $5.25(-0.95%) | 10 Day Moving Average | $5.31(-2.07%) | 20 Day Moving Average | $5.69(-8.61%) | To recent high | -26.2% | To recent low | 1.6% | Market Cap | $272m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |